Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer.
Wei ZhouJiandong HuangQingwei XiaoShunmin HuShijia LiJie ZhengZhiyun DuJiangling PengHuixiong ChenPublished in: Pharmaceutics (2022)
The prostate specific membrane antigen (PSMA), extensively overexpressed on prostate cancer (PCa) cell surface, has been validated as a diagnostic biomarker for PCa. However, insufficient attention has been paid to the development of PSMA-specific probes loaded with small chemical molecules for the in vivo molecular imaging of PCa. In this study, we innovatively labelled superparamagnetic iron oxide nanoparticles with a PSMA-targeting Glu-Urea-Lys scaffold. An optimized synthetic route was developed to offer a physiochemically stable probe. The probe demonstrated high binding affinity (0.38 ± 0.08 μg(Fe)/mL) and binding specificity to PSMA expressed on prostate cancer cell surface in vitro. In a xenograft PCa mouse model, significant negative contrast of the implanted prostate cancer xenograft could be specifically observed by MRI 6 h after tail vein injection of the tracer (Fe, 20 mg/kg), exhibiting its potential to exclusively enhance magnetic resonance detection of PCa.
Keyphrases
- prostate cancer
- iron oxide nanoparticles
- pet ct
- pet imaging
- cell surface
- radical prostatectomy
- magnetic resonance
- contrast enhanced
- quantum dots
- mouse model
- cancer therapy
- positron emission tomography
- magnetic resonance imaging
- living cells
- drug delivery
- computed tomography
- diffusion weighted imaging
- dna binding
- mass spectrometry
- tissue engineering
- ultrasound guided
- fluorescent probe
- photodynamic therapy
- binding protein
- tandem mass spectrometry
- molecularly imprinted